Statement re Mainstay Medical to Host Key Opinion Leader Event on the Chronic Low Back Pain Treatment Landscape

MSTY

DUBLIN--()--

Mainstay Medical to Host Key Opinion Leader Event on the Chronic Low Back Pain Treatment Landscape

Dublin, Ireland -- June 22, 2017 -- Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain (“CLBP”), today announced that it will host a key opinion leader (KOL) lunch to discuss the CLBP landscape in New York City on Monday, June 26, from 12:00pm - 1:30pm Eastern Time.

The meeting will feature presentations by key opinion leaders, Christopher Gilligan, MD (Brigham and Women's Hospital), and Timothy Deer, MD (The Spine and Nerve Centers of the Virginias), who will discuss the clinical perspective and treatment options for patients with CLBP. Both KOLs will be available to answer questions following the lunch.

Mainstay Medical's management team will also provide an overview of the Company’s ongoing clinical development work with ReActiv8, a small implanted neurostimulator that stimulates the nerves responsible for activating the key muscles that stabilize the low back. ReActiv8 is CE marked for the treatment of CLBP and available for sale in Europe, and is in an investigational device exemption trial in the United States to support an application for Pre-Market Approval (PMA).

Christopher Gilligan, MD, is the Chief of the Division of Pain Medicine in the Department of Anesthesiology, Perioperative and Pain Medicine at Brigham and Women’s Hospital. He is also an Assistant Professor of Anesthesia at Harvard Medical School. His team currently treats over 2,000 pain patients each month, and is responsible for treating non-surgical patients at the Comprehensive Spine Center at Brigham and Women's Faulkner Hospital. Dr. Gilligan's clinical expertise is focused on the treatment of pain related to disorders of the spine. He also treats patients with a wide range of pain conditions, including cancer related pain, complex regional pain syndrome, and post-herpetic neuralgia. Dr. Gilligan's research focuses on clinical trials of new interventions, devices and medications for the treatment of pain. He currently serves on the Industry Relations Committee for the American Society of Regional Anesthesia and Pain Medicine and has an interest in pain telemedicine. Dr. Gilligan has been involved with ReActiv8 since the Feasibility Study in 2011, and is presently Principal Investigator of the ReActiv8-B Clinical Trial to gather data for a PMA submission for US approval.

Timothy Deer, MD, is the President and CEO of The Spine and Nerve Centers of the Virginias and the Center for Pain Relief, Inc. He is also a Clinical Professor of Anesthesiology at the West Virginia University School of Medicine. Dr. Deer has been a leader in the field of interventional techniques and neuromodulation for more than two decades. His work has led to more than 100 peer-reviewed publications, several book chapters, and full text books. Dr. Deer’s publications have included guidance for the proper use of neuromodulation to improve safety and efficacy. His textbooks have included comprehensive guidance on pain and implantable devices. His rich research career has included many pivotal studies to achieve FDA approval, and many “first in man” approved devices. Dr. Deer is currently the President of the International Neuromodulation Society (INS) and President of the West Virginia Society of Interventional Pain Physicians (WVSIPP). He is he Past Chairman of the American Society of Anesthesiologist Committee of Pain Medicine and a Member of the West Virginia Controlled Substance Monitoring Program. Dr. Deer is an investigator in the ReActiv8-B Clinical Trial.

This lunch event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com. A live and archived webcast of the event, with slides, will be available at on the investors section of the Company’s website at http://www.mainstay-medical.com/en and http://lifesci.rampard.com/20170626/reg.jsp.

About Mainstay

Mainstay is a medical device company focused on bringing to market an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia and Germany, and its ordinary shares are admitted to trading on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

About Chronic Low Back Pain

One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on individuals, families, communities, industry and governments.

Further information can be found at www.mainstay-medical.com

CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.

PR and IR Enquiries:
Consilium Strategic Communications (international strategic communications – business and trade media)
Chris Gardner, Mary-Jane Elliott, Jessica Hodgson, Hendrik Thys
Tel: +44 203 709 5700 / +44 7921 697 654
Email: mainstaymedical@consilium-comms.com
or
FTI Consulting (for Ireland)
Jonathan Neilan
Tel: +353 1 663 3686
Email: jonathan.neilan@fticonsulting.com
or
NewCap (for France)
Louis-Victor Delouvrier
Tel: +33 1 44 71 20 40
Email: lvdelouvrier@newcap.fr
or
AndreasBohne.Com/Kötting Consulting (for Germany)
Andreas Bohne
Tel: +49 2102 1485368
Email: abo@andreasbohne.com
or
Investor Relations:
LifeSci Advisors, LLC
Brian Ritchie
Tel: + 1 (212) 915-2578
Email: britchie@lifesciadvisors.com
or
ESM Advisers:
Davy
Fergal Meegan or Barry Murphy
Tel: +353 1 679 6363
Email: fergal.meegan@davy.ie or barry.murphy2@davy.ie

Short Name: Mainstay Medical
Category Code: STR
Sequence Number: 586054
Time of Receipt (offset from UTC): 20170622T120614+0100

Contacts

Mainstay Medical International plc

Contacts

Mainstay Medical International plc